Profile of temsirolimus in the treatment of advanced renal cell carcinoma

被引：8
|
作者：
Staehler, Michael [1 ]
Haseke, Nicolas [1 ]
Khoder, Wael [1 ]
Stief, Christian G. [1 ]
机构：
[1] Univ Munich, Dept Urol, Klinikum Grosshadern, D-81377 Munich, Germany
来源：
ONCOTARGETS AND THERAPY | 2010年 / 3卷
关键词：
renal cell cancer; nonclear cell renal cancer; temsirolimus; first-line therapy; overall survival; nephrectomy; INTERFERON-ALPHA; PROGNOSTIC-FACTORS; SURVIVAL; NEPHRECTOMY; CANCER;
D O I：
10.2147/OTT.S7657
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
Temsirolimus is a potent inhibtor of the mammalian target of rapamycin (mTOR). In various clinical trials temsirolimus has shown an overall survival benefit for patients with metastatic renal cell carcinoma (mRCC). Thus it is approved for first-line therapy in high-risk mRCC patients. We discuss the indication, side effects and clinical implications of temsirolimus treatment.
引用
收藏
页码：191 / 196
页数：6
相关论文
共 50 条
  • [31] Phase I Study Combining Treatment with Temsirolimus and Sunitinib Malate in Patients with Advanced Renal Cell Carcinoma
    Patel, Premal H.
    Senico, Peggy L.
    Curiel, Rafael E.
    Motzer, Robert J.
    CLINICAL GENITOURINARY CANCER, 2009, 7 (01) : 24 - 27
  • [32] Re: Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma
    Shariat, Shahrokh F.
    Karam, Jose A.
    Karakiewicz, Pierre I.
    EUROPEAN UROLOGY, 2009, 55 (01) : 250 - 252
  • [33] Temsirolimus for advanced renal cell carcinoma (RCC): Compassionate versus commercial use
    Bojanapally, P. R.
    Graham, S.
    Rustine, A. L.
    Sacris, L. A.
    Dutcher, J. P.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [34] Q-TWiST Analysis of Patients Receiving Temsirolimus or Interferon Alpha for Treatment of Advanced Renal Cell Carcinoma
    Arthur S. Zbrozek
    Gary Hudes
    Donna Levy
    Andrew Strahs
    Anna Berkenblit
    Robert De Marinis
    Shreekant Parasuraman
    PharmacoEconomics, 2010, 28 : 577 - 584
  • [35] Q-TWiST Analysis of Patients Receiving Temsirolimus or Interferon Alpha for Treatment of Advanced Renal Cell Carcinoma
    Zbrozek, Arthur S.
    Hudes, Gary
    Levy, Donna
    Strahs, Andrew
    Berkenblit, Anna
    DeMarinis, Robert
    Parasuraman, Shreekant
    PHARMACOECONOMICS, 2010, 28 (07) : 577 - 584
  • [36] Neoadjuvant Temsirolimus Effectiveness in Downstaging Advanced Non-Clear Cell Renal Cell Carcinoma
    Rodriguez Faba, Oscar
    Breda, Alberto
    Rosales, Antonio
    Palou, Joan
    Algaba, Ferran
    Maroto Rey, Pablo
    Villavicencio, Humberto
    EUROPEAN UROLOGY, 2010, 58 (02) : 307 - 310
  • [37] Treatment of advanced renal cell carcinoma
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2007, 49 (1276): : 103 - 104
  • [38] Economic evaluation of temsirolimus on the basis of the results of the ARCC (Advanced Renal Cell Carcinoma) study
    de Portu, Simona
    Carteni, Giacomo
    Belisari, Andrea
    FARMECONOMIA-HEALTH ECONOMICS AND THERAPEUTIC PATHWAYS, 2009, 10 (02) : 93 - 97
  • [39] "COMPASSIONATE USE" - PROGRAM (CUP) "TEMSIROLIMUS" IN PATIENTS WITH ADVANCED RENAL CELL CARCINOMA IN GERMANY
    Pelz, H. F.
    Baierl, T.
    Wiesmann, K.
    Kosch, M.
    EUROPEAN UROLOGY SUPPLEMENTS, 2009, 8 (04) : 184 - 184
  • [40] Drug-Related Pneumonitis in Patients With Advanced Renal Cell Carcinoma Treated With Temsirolimus
    Pablo Maroto, Jose
    Hudes, Gary
    Dutcher, Janice P.
    Logan, Theodore F.
    White, Charles S.
    Krygowski, Mizue
    Cincotta, Maria
    Shapiro, Mark
    Duran, Ignacio
    Berkenblit, Anna
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (13) : 1750 - 1756
12345